FORMYCON AG(FRA:FYB) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 5 out of 10 to FYB. FYB was compared to 75 industry peers in the Biotechnology industry. FYB has only an average score on both its financial health and profitability. FYB is not overvalued while it is showing excellent growth. This is an interesting combination.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year FYB was profitable.

In the past year FYB has reported a negative cash flow from operations.

The reported net income has been mixed in the past 5 years: FYB reported negative net income in multiple years.

FYB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

FYB has a better Return On Assets (6.74%) than 92.65% of its industry peers.

Looking at the Return On Equity, with a value of 11.09%, FYB belongs to the top of the industry, outperforming 89.71% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	6.74%
ROE	11.09%
ROIC	N/A

ROA(3y)-2.02%

ROA(5y)-3.74%

ROE(3y)0.46%

ROE(5y)-2.68%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 105.09%, FYB belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

FYB's Profit Margin has improved in the last couple of years.

FYB's Gross Margin of 12.46% is in line compared to the rest of the industry. FYB outperforms 44.12% of its industry peers.

FYB's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	105.09%
GM	12.46%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y42.78%

GM growth 3Y9.85%

GM growth 5Y-7.6%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FYB does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, FYB has more shares outstanding

FYB has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, FYB has an improved debt to assets ratio.

2.2 Solvency

FYB has an Altman-Z score of 1.72. This is a bad value and indicates that FYB is not financially healthy and even has some risk of bankruptcy.

FYB's Altman-Z score of 1.72 is fine compared to the rest of the industry. FYB outperforms 63.24% of its industry peers.

FYB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.

FYB's Debt to Equity ratio of 0.02 is fine compared to the rest of the industry. FYB outperforms 75.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Altman-Z	1.72

ROIC/WACCN/A

WACC6.67%

2.3 Liquidity

FYB has a Current Ratio of 2.10. This indicates that FYB is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of FYB (2.10) is worse than 60.29% of its industry peers.

A Quick Ratio of 2.06 indicates that FYB has no problem at all paying its short term obligations.

With a Quick ratio value of 2.06, FYB perfoms like the industry average, outperforming 44.12% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.1
Quick Ratio	2.06

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 243.10% over the past year.

FYB shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 44.36% yearly.

The Revenue for FYB has decreased by -11.42% in the past year. This is quite bad

FYB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.47% yearly.

EPS 1Y (TTM)243.1%

EPS 3YN/A

EPS 5Y44.36%

EPS Q2Q%-616.42%

Revenue 1Y (TTM)-11.42%

Revenue growth 3Y31.34%

Revenue growth 5Y12.47%

Sales Q2Q%-38.59%

3.2 Future

FYB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.98% yearly.

Based on estimates for the next years, FYB will show a very strong growth in Revenue. The Revenue will grow by 23.80% on average per year.

EPS Next Y-125.43%

EPS Next 2Y-67.4%

EPS Next 3Y23.11%

EPS Next 5Y22.98%

Revenue Next Year-22.49%

Revenue Next 2Y7.11%

Revenue Next 3Y32.23%

Revenue Next 5Y23.8%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 7.64, the valuation of FYB can be described as very cheap.

Compared to the rest of the industry, the Price/Earnings ratio of FYB indicates a rather cheap valuation: FYB is cheaper than 98.53% of the companies listed in the same industry.

Compared to an average S&P500 Price/Earnings ratio of 30.42, FYB is valued rather cheaply.

With a Price/Forward Earnings ratio of 134.01, FYB can be considered very expensive at the moment.

Based on the Price/Forward Earnings ratio, FYB is valued a bit cheaper than 73.53% of the companies in the same industry.

The average S&P500 Price/Forward Earnings ratio is at 23.75. FYB is valued rather expensively when compared to this.

		Industry Rank	Sector Rank
PE	7.64
Fwd PE	134.01

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

FYB's earnings are expected to grow with 23.11% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)0.17

EPS Next 2Y-67.4%

EPS Next 3Y23.11%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

FYB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

FORMYCON AG

FRA:FYB (2/20/2025, 5:29:31 PM)

30.55

+0.65 (+2.17%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-28 2024-11-28

Earnings (Next)03-27 2025-03-27/amc

Inst Owners10.81%

Inst Owner ChangeN/A

Ins Owners5.92%

Ins Owner ChangeN/A

Market Cap539.51M

Analysts85.33

Price Target93.04 (204.55%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0.2%

PT rev (3m)1.41%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)-11.34%

EPS NY rev (3m)-11.34%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)11%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-1.74%

Valuation

		Industry Rank	Sector Rank
PE	7.64
Fwd PE	134.01
P/S	8.87
P/FCF	N/A
P/OCF	N/A
P/B	0.94
P/tB	78.8
EV/EBITDA	N/A

EPS(TTM)4

EY13.09%

EPS(NY)0.23

Fwd EY0.75%

FCF(TTM)-3.34

FCFYN/A

OCF(TTM)-1.85

OCFYN/A

SpS3.44

BVpS32.63

TBVpS0.39

PEG (NY)N/A

PEG (5Y)0.17

Profitability

		Industry Rank	Sector Rank
ROA	6.74%
ROE	11.09%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	105.09%
GM	12.46%
FCFM	N/A

ROA(3y)-2.02%

ROA(5y)-3.74%

ROE(3y)0.46%

ROE(5y)-2.68%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y42.78%

GM growth 3Y9.85%

GM growth 5Y-7.6%

F-Score3

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	1273.47%
Cap/Sales	43.19%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.1
Quick Ratio	2.06
Altman-Z	1.72

F-Score3

WACC6.67%

ROIC/WACCN/A

Cap/Depr(3y)872.92%

Cap/Depr(5y)553.96%

Cap/Sales(3y)30.94%

Cap/Sales(5y)19.51%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)243.1%

EPS 3YN/A

EPS 5Y44.36%

EPS Q2Q%-616.42%

EPS Next Y-125.43%

EPS Next 2Y-67.4%

EPS Next 3Y23.11%

EPS Next 5Y22.98%

Revenue 1Y (TTM)-11.42%

Revenue growth 3Y31.34%

Revenue growth 5Y12.47%

Sales Q2Q%-38.59%

Revenue Next Year-22.49%

Revenue Next 2Y7.11%

Revenue Next 3Y32.23%

Revenue Next 5Y23.8%

EBIT growth 1Y-765.5%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-170.47%

EBIT Next 3Y166.73%

EBIT Next 5Y90.04%

FCF growth 1Y-223.02%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-106.26%

OCF growth 3YN/A

OCF growth 5YN/A

FORMYCON AG (FYB.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens